Biocytogen Pharmaceuticals (Beijing) Co Ltd is a China-based company primarily engaged in the provision of innovative animal models and pre-clinical pharmaceutical research and development services based on its independently developed gene-editing technology. The Company utilizes its self-developed RenMice fully human antibody and T-cell receptor (TCR) mouse platform for large-scale drug discovery and development targeting potential drug targets in the human body. The Companyâ€™s main businesses include the sale of innovative animal models, pre-clinical pharmacology and efficacy evaluation services, and antibody development. The Company is also engaged in the provision of gene-editing services. The Company operates its businesses in the domestic market and overseas markets.

Employees

1,443

Sector

Biotechnology & Medical Research

Calendar

08-27 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-08-20	CN¥61.10	+1.08%	3,438,404
26-08-19	CN¥60.45	-4.35%	1,267,146
26-08-18	CN¥63.20	-0.78%	839,690
26-08-17	CN¥63.70	-7.68%	3,867,660
26-08-14	CN¥69.00	-1.78%	1,108,210

End-of-day quote Hong Kong S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

52.40CNY

Average target price

53.66CNY

Spread / Average Target

+2.40%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

End-of-day quote Hong Kong S.E. 2026-08-20			5-day change	1st Jan Change
61.10 ^CNY	+1.08%		-13.02%	+73.09%

08-07	Biocytogen Pharmaceuticals Expects H1 Profit to Soar by Up to 413%; Shares Up 10%	MT
08-06	Biocytogen Pharmaceuticals Co., Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2026	CI

Market Cap	52.25B 7.77B 6.65B 6.21B 5.69B 10.7B 743B 10.91B 73.62B 28.7B 373B 29.17B 28.53B 1,233B	P/E 2026 *	60.9x	P/E 2027 *	38.7x
Enterprise Value	52.25B 7.77B 6.65B 6.21B 5.69B 10.7B 743B 10.91B 73.62B 28.7B 373B 29.17B 28.53B 1,233B	EV / Sales 2026 *	26.9x	EV / Sales 2027 *	19.8x
Free-Float	74.79%	Yield 2026 *	-	Yield 2027 *	-

08-07	Biocytogen Pharmaceuticals Expects H1 Profit to Soar by Up to 413%; Shares Up 10%	MT
08-06	Biocytogen Pharmaceuticals Co., Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2026	CI
07-07	Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody Adc Development	CI
06-29	Shanghai Court Dismisses HBM Subsidiary's Patent Infringement Claim Against Biocytogen	MT
06-29	Chinese Biopharma Stocks Rally as Investors Favor Healthcare Over AI	DJ
06-21	Biocytogen Pharmaceuticals Co., Ltd.(XSSC:688796) added to S&P Global BMI Index	CI
05-26	Biocytogen Launches Rensuper Workstation and Rensuper High-Throughput Antibody Manufacturing Automation Center	CI
04-27	Biocytogen Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-27	Biocytogen Pharmaceuticals Turns to Profit in Q1	MT
04-01	Biocytogen Pharmaceuticals, Sihuan Pharmaceutical Enter Strategic Partnership	MT
04-01	Biocytogen Pharmaceuticals and Sihuan Pharmaceutical Holdings Group Announce Strategic Partnership in Weight Loss and Beyond	CI
03-30	Biocytogen Pharmaceuticals Grants Taisho Pharmaceutical A License to RenNano Fully Human Heavy Chain-Only Antibody Discovery Platform	CI
03-27	Biocytogen Pharmaceuticals' 2025 Profit Surges as Revenue Rises 41%	MT

07-07	Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development	BU
07-07	Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development	BU
06-29	Court Clears Biocytogen’s RenNano® in Landmark Patent Dispute Against Harbour	BU
06-29	Court Clears Biocytogen’s RenNano® in Landmark Patent Dispute Against Harbour	BU
06-15	Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery	BU

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Stock

Stocks

2315

CNE100005D27

Biotechnology & Medical Research

Valuation: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Chart: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Latest news : Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Press Releases: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

News in other languages: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

07-07	Biocytogen et Whitehawk Therapeutics concluent une collaboration mondiale pour le développement d’ADC à anticorps bispécifiques
07-07	Biocytogen und Whitehawk Therapeutics vereinbaren weltweite Zusammenarbeit zur Entwicklung von bispezifischen Antikörper-Wirkstoff-Konjugaten (ADC)
06-29	Gericht gibt Biocytogen im wegweisenden Patentstreit gegen Harbour in Bezug auf RenNano® Recht
06-29	MÄRKTE ASIEN/Positive Vorzeichen überwiegen - Anleger setzen auf Ende des Iran-Kriegs
06-29	MÄRKTE ASIEN/Uneinheitlich - Pharmawerte in China haussieren

1 day	+1.08%
1 week	-13.02%
Current month	+21.83%
1 month	+15.28%
3 months	+20.75%
6 months	+16.16%
Current year	+73.09%

1 week	60.05	69.05
1 month	46.52	75.3
Current year	33.14	75.3
1 year	20.3	75.3
3 years	5.6	75.3
5 years	5.6	75.3
10 years	5.6	75.3

Manager	Title	Age	Since
Yue Lei Shen CEO	Chief Executive Officer	57	2009-11-12
Liu Bin DFI	Director of Finance/CFO	58	2020-01-04
Sabrina Wang COO	Chief Operating Officer	47	2019-09-30

Director	Title	Age	Since
Yue Lei Shen CHM	Chairman	57	2013-01-21
Ke Xiang Zhou BRD	Director/Board Member	62	2018-03-11
Jian Ni CHM	Chairman	55	2009-11-12

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/12/26	Yan Li	Other	Director	1,000	0.0009%
9/26/25	Jian Ni	Other	Director	1,300,500	1.1739%
9/26/25	Jian Ni	Other	Director	1,300,500	1.1739%

	2026 *	2027 *
Net sales	1.94B 289M 247M 231M 212M 398M 27.66B 406M 2.74B 1.07B 13.86B 1.09B 1.06B 45.89B	2.64B 392M 336M 313M 287M 540M 37.53B 551M 3.72B 1.45B 18.81B 1.47B 1.44B 62.27B
Net income	384M 57.09M 48.88M 45.61M 41.85M 78.64M 5.46B 80.19M 541M 211M 2.74B 214M 210M 9.06B	605M 89.95M 77.01M 71.86M 65.93M 124M 8.61B 126M 852M 332M 4.31B 338M 330M 14.28B
Net Debt	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.	+1.08%	-13.02%	+172.77%	+301.45%	7.77B
LONZA GROUP AG	+1.14%	+2.27%	+2.38%	+24.14%	51.22B
REVOLUTION MEDICINES, INC.	-1.36%	+4.82%	+485.55%	+614.84%	45.38B
BEONE MEDICINES AG	-2.04%	+3.69%	+19.34%	+91.23%	41.97B
IQVIA HOLDINGS INC.	+2.72%	+6.02%	+33.33%	+19.66%	42.15B
CELLTRION, INC.	0.00%	-3.91%	+18.49%	+47.98%	31.95B
ASCENDIS PHARMA A/S	-1.85%	+3.48%	-	-	16.73B
MEDPACE HOLDINGS, INC.	+0.72%	+5.27%	+31.55%	+145.37%	17.1B
EUROFINS SCIENTIFIC SE	+3.06%	+3.88%	+5.81%	+35.00%	14.76B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.50%	+3.62%	+82.64%	+46.53%	13.91B
Average	+0.40%	+1.77%	+94.65%	+147.35%	28.29B
Weighted average by Cap.	+0.24%	+2.78%	+105.49%	+155.22%